Phase III randomized double-blind placebo-controlled multi-centre study assessing the efficacy and safety of durvalumab versus placebo as treatment following SBRT in patients with Stage I/II non small cell lung cancer.
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Non-small Cell Lung Cancer
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Histologically or cytologically documented Stage I to II NSCLC, with clinical Stage I/II lymph node-negative (T1 to T3N0M0) disease and planned to receive definitive treatment with SBRT 2) Life expectancy of at least 12 weeks 3) Body weight >30 kg 4) Tumor sample required 5) Adequate organ and marrow function required 6) Patients with central or peripheral lesions are eligible
You may not be eligible for this study if the following are true:
-
1) Mixed small cell and non-small cell cancer histology 2) History of allogeneic organ transplantation 3) History of another primary malignancy with exceptions 4) History of active primary immunodeficiency 5) Any unresolved toxicity National Cancer Institute
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
